Atara Biotherapeutics, Inc.
tabelecleucel
EBV+ PTLD
Countdown
86days
Catalyst readout · ~ Sep 30, 2026 estimated
What's at stake
A key catalyst for tabelecleucel (EBV+ PTLD) is expected ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 13h ago
“We will continue to support Pierre Fabre as it prepares the resubmission and anticipate providing a further regulatory update in the third quarter.”